Therapeutic strategies for treatment of psoriasis that focus on selective inhibition of IL-2312 have demonstrated efficacy in Phase II and Phase III studies.13–17 Tildrakizumab is a biological agent developed to selectively target the p19 subunit of IL-23 and is approved for the treatment of moderate-to-severe psoriasis in both the European Union (EU; Ilumetri®) and United States (US; Ilumya®).18 In its pivotal Phase III reSURFACE 1 and reSURFACE 2 trials, the efficacy and safety of tildrakizumab was investigated compared with placebo and etanercept, a tumor necrosis factor inhibitor. The gene discussed is IL37; the disease is psoriasis.